A2M Therapy at PHI is performed by board-certified physicians Dr. Faisal Lalani and Dr. Nadiv Samimi at our Beverly Hills practice under image guidance. An emerging regenerative protocol, it concentrates alpha-2-macroglobulin from your own blood to neutralize the enzymes that break down joint cartilage, most often for early-to-moderate joint arthritis.
What A2M Therapy Is
Alpha-2-macroglobulin, or A2M, is a large protein produced naturally by your liver and present in your blood. Its primary job is to neutralize harmful enzymes that would otherwise damage tissue. In the joint, A2M acts as a kind of biological filter, capturing and inactivating the specific cartilage-destroying enzymes that drive the progression of osteoarthritis.
When a joint is injured, the body produces protein classes that degrade cartilage. A2M is a powerful inhibitor of three of these classes: cytokines, matrix metalloproteinases, and ADAMTS (a disintegrin and metalloproteinase with thrombospondin). By trapping these proteins so the body can clear them, A2M can slow the progression of osteoarthritis and support a healthier environment for cartilage recovery.
A2M Therapy delivers a concentrated form of A2M, derived from your own blood, directly into the affected joint. This is a different mechanism than corticosteroid injections (which reduce inflammation broadly) or PRP (which delivers growth factors to support tissue repair). A2M is more specifically targeted at the enzymes that drive cartilage degradation.
How A2M Therapy Works
The procedure begins with a blood draw. Your blood is processed through a specialized filtration system that separates and concentrates the A2M protein. The resulting concentrate is then injected directly into the affected joint under image guidance, most often fluoroscopy with an imaging specialist.
The entire process is completed in a single visit. The blood draw, processing, and injection together typically take 60 to 90 minutes.
Because A2M is derived from your own blood, the rejection and immune response risks associated with foreign biologics are not a concern. This is one of A2M’s clinical advantages.
Conditions We Treat with A2M Therapy
A2M Therapy is most appropriate for:
- Knee osteoarthritis, particularly early-to-moderate stages (Kellgren-Lawrence grade 2 or 3)
- Hip osteoarthritis, in selected patients
- Shoulder arthritis, in selected patients
- Other joint conditions where cartilage breakdown is the primary concern
- Patients who want to slow disease progression rather than only manage symptoms
A2M is generally less appropriate for end-stage arthritis where significant cartilage loss has already occurred. In those cases, your physician may recommend stem cell therapy, joint replacement, or other interventions.
What the Evidence Shows
A2M is an emerging regenerative protocol. The early clinical research is promising, but the body of evidence is smaller than for PRP or corticosteroid injections.
A 2024 randomized controlled trial compared A2M-rich injections to PRP and methylprednisolone in patients with mild-to-moderate knee osteoarthritis. The A2M group showed statistically significant improvement on multiple validated pain and function scores at 12 weeks. Importantly, the differences between the A2M, PRP, and corticosteroid groups were not statistically significant in head-to-head comparison, meaning A2M is comparable to but not clearly superior to these alternatives in current trial data.
We tell you this because honest framing matters. A2M has a strong biological rationale and emerging supportive evidence. It is not yet established as superior to other regenerative options. Your physician will discuss whether A2M, PRP, stem cell therapy, or a combination fits your specific situation.
Why Patients Choose PHI for A2M Therapy
Physician-administered, every step
Your blood draw, processing, and injection are all performed under physician oversight by Dr. Faisal Lalani or Dr. Nadiv Samimi.
Image-guided injection
A2M concentrate is delivered under image guidance, most often fluoroscopy with an imaging specialist, to confirm precise placement within the joint capsule.
Honest framing of evidence
A2M is one regenerative option among several. PHI presents A2M alongside PRP and stem cell therapy with frank discussion of the relative evidence for each. We do not push a single protocol as the answer for everyone.
Integrated regenerative menu
PHI offers the full range of regenerative options including PRP, A2M, and multiple stem cell protocols, so you receive the protocol that fits your situation rather than the only one a practice happens to offer.
Concierge, coordinated care
Single-physician continuity from consultation through treatment and return to activity. Patients receive clear guidance and transparent pricing at consultation.
What to Expect
Preparation
Your physician confirms candidacy through review of imaging, physical exam, and treatment history. Some medications, including certain anti-inflammatories, may need to be paused before the procedure.
The procedure
You arrive for a single visit lasting 60 to 90 minutes. Blood is drawn and processed during the visit, and the concentrated A2M is then injected into the affected joint under image guidance.
Recovery
You can leave immediately, and most patients drive themselves home. Activity restrictions for the first week are typically modest, with gradual return to normal activity over several weeks.
Onset
A2M does not produce immediate relief. The effect develops gradually as the protein neutralizes inflammatory enzymes within the joint. Most patients begin to notice improvement by 4 to 6 weeks.
Full benefit
Maximum benefit typically develops by 8 to 12 weeks. Duration of relief varies by individual and underlying condition; some patients experience benefits lasting 6 to 12 months from a single treatment.
Frequently Asked Questions
A2M Therapy uses your own blood, processed and reinjected, which falls under the FDA’s regulations for autologous biologics, similar to PRP. The procedure itself is not FDA-approved as a specific drug for a specific indication; it is a clinical application of an autologous biologic protocol.
PRP delivers growth factors to support tissue repair. A2M delivers a concentrated protease inhibitor that neutralizes cartilage-destroying enzymes. They work through different mechanisms and may be more appropriate for different patients. Some patients receive both.
Cortisone reduces inflammation broadly. A2M specifically targets the enzymes that destroy joint cartilage. Cortisone provides faster but typically shorter relief; A2M provides slower but potentially more sustained protection of the underlying cartilage.
A2M does not produce immediate relief. Most patients begin to notice improvement at 4 to 6 weeks, with maximum benefit at 8 to 12 weeks.
Duration varies. Some patients experience benefits lasting 6 to 12 months from a single treatment. Repeat treatment can be performed when relief diminishes.
Because A2M uses your own blood, immune rejection and disease transmission risks are not a concern. Standard procedural risks include temporary pain or swelling at the injection site, bleeding, and rare infection. Your physician will review the complete risk profile during consultation.
Yes. Some patients benefit from combined or sequential A2M and PRP protocols. Your physician will discuss whether this fits your specific situation.
PHI is out-of-network with all insurance plans. Pricing varies by joint and protocol, and all costs are disclosed at consultation, with no surprise billing.
Yes. PHI regularly treats patients from outside Los Angeles, including Las Vegas, Palm Springs, London, and other international locations.